PURPOSE: Oral leukoplakia (OPL) is a heterogeneous oral lesion with an increased oral cancer risk. Current clinical parameters cannot predict the potential of malignant transformation in patients with OPL. We have shown that podoplanin, a lymphatic endothelial marker, is highly expressed in oral cancer and some oral premalignancies. The purpose of this study is to determine a role of podoplanin in predicting oral cancer development in patients with OPL. PATIENTS AND METHODS: Podoplanin expression was determined in 150 OPL patients with long-term follow-up using immunohistochemistry. Association between the protein expression patterns and clinicopathologic parameters including oral cancer development during the follow-up were analyzed. RESULTS: Fifty-six (37%) of the 150 OPL patients exhibited podoplanin expression in the basal and suprabasal layers and were classified as podoplanin positive. Podoplanin positivity was more frequent in older patients (P = .016), females (P = .020), and dysplastic lesions (P = .040). Patients with OPL that was podoplanin positive had significantly higher incidence of oral cancer than did those whose OPL was podoplanin negative (P = .0002). In the multivariate analysis using histology and podoplanin as cofactors, podoplanin was the only independent factor for oral cancer development (hazard ratio = 3.087; 95% CI, 1.530 to 6.231; P = .002). Importantly, oral cancer risk can be further stratified by considering both histology and podoplanin information. CONCLUSION: Podoplanin is frequently expressed in OPL. Together with histology, podoplanin may serve as a powerful biomarker to predict the risk for oral cancer development in patients with OPL.
PURPOSE:Oral leukoplakia (OPL) is a heterogeneous oral lesion with an increased oral cancer risk. Current clinical parameters cannot predict the potential of malignant transformation in patients with OPL. We have shown that podoplanin, a lymphatic endothelial marker, is highly expressed in oral cancer and some oral premalignancies. The purpose of this study is to determine a role of podoplanin in predicting oral cancer development in patients with OPL. PATIENTS AND METHODS: Podoplanin expression was determined in 150 OPL patients with long-term follow-up using immunohistochemistry. Association between the protein expression patterns and clinicopathologic parameters including oral cancer development during the follow-up were analyzed. RESULTS: Fifty-six (37%) of the 150 OPL patients exhibited podoplanin expression in the basal and suprabasal layers and were classified as podoplanin positive. Podoplanin positivity was more frequent in older patients (P = .016), females (P = .020), and dysplastic lesions (P = .040). Patients with OPL that was podoplanin positive had significantly higher incidence of oral cancer than did those whose OPL was podoplanin negative (P = .0002). In the multivariate analysis using histology and podoplanin as cofactors, podoplanin was the only independent factor for oral cancer development (hazard ratio = 3.087; 95% CI, 1.530 to 6.231; P = .002). Importantly, oral cancer risk can be further stratified by considering both histology and podoplanin information. CONCLUSION:Podoplanin is frequently expressed in OPL. Together with histology, podoplanin may serve as a powerful biomarker to predict the risk for oral cancer development in patients with OPL.
Authors: Juan P Rodrigo; Juana María García-Pedrero; Carlos Suárez; Robert P Takes; Lester D R Thompson; Pieter J Slootweg; Julia A Woolgar; William H Westra; Ruud H Brakenhoff; Alessandra Rinaldo; Kenneth O Devaney; Michelle D Williams; Douglas R Gnepp; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2011-11-12 Impact factor: 2.503
Authors: Yukinari Kato; Ganesan Vaidyanathan; Mika Kato Kaneko; Kazuhiko Mishima; Nidhi Srivastava; Vidyalakshmi Chandramohan; Charles Pegram; Stephen T Keir; Chien-Tsun Kuan; Darell D Bigner; Michael R Zalutsky Journal: Nucl Med Biol Date: 2010-10 Impact factor: 2.408
Authors: Pierre Saintigny; Adel K El-Naggar; Vali Papadimitrakopoulou; Hening Ren; You-Hong Fan; Lei Feng; J Jack Lee; Edward S Kim; Waun Ki Hong; Scott M Lippman; Li Mao Journal: Clin Cancer Res Date: 2009-09-22 Impact factor: 12.531
Authors: Eric M Genden; Alfio Ferlito; Carl E Silver; Robert P Takes; Carlos Suárez; Randall P Owen; Missak Haigentz; Sandro J Stoeckli; Ashok R Shaha; Alexander D Rapidis; Juan Pablo Rodrigo; Alessandra Rinaldo Journal: Eur Arch Otorhinolaryngol Date: 2010-02-13 Impact factor: 2.503
Authors: Juan P Rodrigo; Dario García-Carracedo; María V González; Gonzalo Mancebo; Manuel F Fresno; Juana García-Pedrero Journal: Mol Cancer Date: 2010-03-02 Impact factor: 27.401